EICHORCondition: Diabetic Nephropathy · Sponsor: Chen Xiangmei
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality. Despite current standard therapies including renin-angiotensin system inhibitors (ACEI/ARB), glycemic control, and blood pressure management, disease progression remains inadequately controlled in many patients. Naoxintong Capsule is a traditional Chinese medicine formulation composed of 16 herbal ingredients (Astragalus membranaceus, Prunus persica seed, Carthamus tinctorius, Paeonia lactiflora, Angelica sinensis, Ligusticum chuanxiong, Boswellia carterii, Commiphora myrrha, Salvia miltiorrhiza, Achyranthes bidentata, Cinnamomum cassia, Morus alba, Spatholobus suberectus, Buthus martensii, Pheretima aspergillum, and Hirudo nipponica). It has been widely used in China for cardiovascular and cerebrovascular diseases, with demonstrated effects on endothelial protection, anti-inflammation, anti-thrombosis, and plaque stabilization. This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Naoxintong Capsule added to standard conventional therapy in slowing the progression of diabetic nephropathy and providing cardiovascular protection. A total of 410 patients with Type 2 diabetic nephropathy will be randomized (1:1) to receive either Naoxintong Capsules (4 capsules, 3 times daily) or matching placebo, in addition to standard therapy, for 12 months. The primary outcome…
This description comes directly from the study's public registry record.
Zheyi Dong, MD · 010-66937763 · shengdai26@163.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Age \>= 18 years. 2. Meets the diagnostic criteria for Type 2 diabetic nephropathy, defined as: 1. Confirmed diagnosis of Type 2 diabetes mellitus; AND 2. At least one of the following: urinary albumin-to-creatinine ratio (UACR) \>= 30 mg/g, or eGFR \< 60 mL/min/1.73m\^2, confirmed by repeat testing (interval \>= 3 months), after excluding transient factors such as acute kidney injury, dehydration, infection, or heart failure; OR 3. Renal biopsy confirmed as isolated diabetic nephropathy; AND 4. Exclusion of other primary or secondary kidney diseases. 3. 24-hour urinary protein excretion \>= 0.5 g and \< 3.5 g. 4. Estimated glomerular filtration rate (eGFR) \>= 45 mL/min/1.73m\^2. 5. On a stable dose of ACE inhibitor (ACEI) or Angiotensin II receptor blocker (ARB) therapy for at least 8 weeks prior to enrollment. If SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), or GLP-1 receptor agonists are being used, the dose must have been stable for at least 4 weeks prior to enrollment and remain unchanged during the study period. Patients not currently using these agents must not initiate them during the study. 6. Signed informed consent form. Exclusion Criteria: 1. Type 1 diabetes mellitus or other types of diabetes mellitus (e.g., secondary diabetes, maturity-onset diabetes of the young). 2. Coexisting systemic autoimmune or immune-mediated disease where the clinical assessment suggests a non-diabetic nephropathy etiology. 3. Decline in eGFR of \> 30% within the past 3 months. 4. Persistent serum potassium \> 5.5 mmol/L. 5. Diagnosis of hemorrhagic cardiovascular or cerebrovascular disease within the past 3 months. 6. Known allergy or hypersensitivity to any component of Naoxintong Capsule or placebo; pregnant or lactating women. 7. Participation in another drug or medical device clinical trial within the past 6 months. 8. Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in the clinical trial (e.g., severe hepatic dysfunction, life expectancy \< 1 year).
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Chinese PLA General Hospital, First Medical Center | Beijing, Beijing Municipality, China | — |
| China-Japan Friendship Hospital | Beijing, Beijing Municipality, China | — |
| Daping Hospital, Army Medical University | Chongqing, Chongqing Municipality, China | — |
| First Affiliated Hospital of Dalian Medical University | Dalian, Liaoning, China | — |
| Longhua Hospital, Shanghai University of Traditional Chinese Medicine | Shanghai, Shanghai Municipality, China | — |
| Renji Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | — |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | — |
| Zhejiang Provincial Hospital of Traditional Chinese Medicine | Hangzhou, Zhejiang, China | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07698223